Delivers up-to-date industry news on topics like drug approvals, product recalls, company expansions and acquisitions, market trends for all OSD forms, as well as excipients, packaging and supply chain issues. Monitors market trends in specific drug categories as well as in supplements/nutraceuticals. Provides updates on clinical trials. Includes alerts about new or upcoming regulatory issues.
Sabal therapeutics, LLC announced that they have entered into an exclusive sales and marketing agreement with Athena Bioscience, LLC to promote Athena's cardiovascular product portfolio.
read more
Desert Harvest, a manufacturer of nutritional supplements formulated with a proprietary super-concentrated aloe vera extract, today announced that it plans to phase out single-use plastic bottles for all of its products by the end of 2022.
read more
AbbVie announced positive top-line results from U-EXCEL, a Phase 3 induction study, showing upadacitinib (45 mg once daily) achieved both primary endpoints of clinical remissiona, and endoscopic response at week 12.1
read more
Trevi Therapeutics announced positive interim analysis results of the Phase 2 Cough And NALbuphine (CANAL) trial of its investigational therapy Haduvio™ (nalbuphine ER) in idiopathic pulmonary fibrosis patients (IPF) suffering from chronic cough, establishing proof of concept.
read more
Merck announced an extension to the label for metformin products in the EU - Glucophage® (metformin hydrochloride [HCL] immediate release), Glucophage XR® (metformin HCL extended release) and Stagid® (metformin embonate immediate release) - for use throughout pregnancy.
read more
Biohaven Pharmaceutical Holding Company Ltd. and Pfizer Inc. announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion for rimegepant, a calcitonin gene-related peptide (CGRP) receptor antagonist.
read more
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, presented data for its lead oral drug candidate, KVD900, in development for on-demand treatment of hereditary angioedema (HAE), at the American Academy of Allergy, Asthma &...
read more
Lynk Pharmaceuticals Co. announced that it had dosed the first patient with LNK01001 in its Phase II clinical trial on subjects with atopic dermatitis (AD).
read more
Accord Healthcare, a generic pharmaceutical company, has added Pirfenidone to its oral solid products portfolio. The new drug is therapeutically equivalent to Genentech's Esbriet and approved to treat idiopathic pulmonary fibrosis (IPF), a lung disease that involves scarring of the lungs with an unknown cause.
read more
Eli Lilly and Company announced updated data from the Phase 1/2 LIBRETTO-001 trial of Retevmo® (selpercatinib 40 mg & 80 mg capsules) in patients with RET fusion-positive non-small cell lung cancer (NSCLC).
read more
The global vitamins and supplements market size was valued at USD 108.4 Billion in 2021 and is expected to register a CAGR of 6.7% during the forecast period, according to the latest analysis by Emergen Research.
read more
The global empty capsules market was valued at $2,382.7 million in 2020, and is projected to reach $5,230.4 million by 2030, registering a CAGR of 8.1% from 2021 to 2030, according to a report by ResearchandMarkets.com.
read more
Ascletis Pharma Inc. has submitted marketing authorization applications for ritonavir (100 mg film-coated tablet) in eight additional European countries (Spain, Portugal, Italy, Belgium, Poland, Sweden, the Netherlands and Denmark) through its agent in Europe.
read more
Aceto, a supplier for life sciences and advanced technology specialty ingredients, announced the acquisition of Biotron Laboratories and Talus Mineral Company (affiliated entities collectively referred to as Biotron herein), manufacturers of specialty ingredients for the nutritional supplements industry.
read more
Senores Pharmaceuticals, Inc. announced the launch of Mexiletine Hydrochloride Capsules USP, 150 mg, 200 mg and 250 mg, a therapeutic equivalent version of MEXITIL (Mexiletine Hydrochloride) with one of the top 5 generic pharmaceutical companies in the U.S. market.
read more